Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Post by FarmerBettyon Feb 27, 2023 7:26pm
331 Views
Post# 35308426

Gbathat the second Boston Group mole is surfacing!!

Gbathat the second Boston Group mole is surfacing!!The PR by Promisneurosciences in August/21 which says "we expect our cash is sufficient to finance the company's operations for the next twelve months". No different projects identified for cash moving forward with an IND filing for AD. Suddenly Ocober/21 another PP to the Boston group reportedly needed for advancing the IND filing?? Shortly after Gbathat blogged that Acumen is funded through 2024. "but i think the Boston group will buy in at $5/share to get them there". Meaning Promis!!

Exactly at that price of $5 on the Nasdaq, no news for months, low low volume naturally perfectly executed by the Boston group Mike Gordon and Jeremy Sclar amongst others. Acumen a one trick pony with AD raised millions at a much higher share price.  Promis has AD, ALS and PD porfolio's on the go.  Let's see what materializes?? Is the Boston fix in ?? or is something else happening ??

<< Previous
Bullboard Posts
Next >>